UK first in Europe to approve Novo Nordisk's Wegovy pill

The United Kingdom has become the first European nation to approve Novo Nordisk's groundbreaking weight-loss medication, Wegovy, in an easily digestible pill form. The pharmaceutical giant anticipates that the medication will be accessible to British patients via prescription in the coming weeks.

While the pill has yet to receive approval within the European Union, the European Medicines Agency (EMA) issued a positive recommendation for its authorization at the close of May. This recommendation has now been forwarded to the EU Commission for a final decision on whether to permit the sale and marketing of the pill across EU member states.

This development comes shortly after Novo Nordisk disclosed that it had been the target of a cyberattack. The incident affected some of the company's internal IT systems, prompting an investigation with the assistance of external cybersecurity experts and contact with relevant authorities. Novo Nordisk has assured that its core business operations were not impacted and continue to function normally, although some internal systems were temporarily shut down. The company is actively working to restore these affected systems in a controlled and secure manner.

“

Vi arbejder på at få de berørte systemer op at køre igen på en kontrolleret og sikker måde.